Gastroenterology · Medical Literature
Helicobacter pylori Eradication in the Era of Rising Antibiotic Resistance: A Randomized Controlled Comparison of Clarithromycin- and Levofloxacin-Based Triple Therapy with or without Lactoferrin.
Abstract
Helicobacter pylori infection affects nearly half of the global population and is a major cause of peptic ulcer disease and gastric cancer. Increasing antibiotic resistance, particularly to clarithromycin, has reduced the efficacy of standard triple therapy, necessitating evaluation of alternative regimens and adjunctive therapies. To compare the eradication rates and safety of clarithromycin- and levofloxacin-based triple therapy, with and without adjunctive lactoferrin. In this randomized, open-label, 2 × 2 factorial trial, 160 adult patients with confirmed H. pylori infection were allocated equally into four groups: clarithromycin-based triple therapy, levofloxacin-based triple therapy, and each regimen combined with lactoferrin. Treatments were administered for 14 days. Eradication was assessed using stool antigen testing four weeks after therapy. Analysis was performed according to the intention-to-treat principle. Eradication rates were 72.5% in both the clarithromycin and levofloxacin groups, compared with 90.0% and 97.5% in the corresponding lactoferrin-supplemented groups, respectively (p = 0.003). Lactoferrin significantly improved eradication rates (72.5% vs. 93.8%, p < 0.001). No significant difference was observed between antibiotic regimens alone (p = 0.673). Adverse events were mild and comparable across groups. Adjunctive lactoferrin significantly enhances H. pylori eradication rates when combined with standard triple therapy, regardless of antibiotic backbone. The evidence proves that lactoferrin should function as an effective adjunct in eradication regimens, particularly in settings of increasing antibiotic resistance.
Clinical relevance
In adult patients with confirmed Helicobacter pylori infection, do clarithromycin-based or levofloxacin-based 14-day triple therapy regimens differ in eradication efficacy, and does adjunctive lactoferrin supplementation improve eradication rates across both regimens? __SNAPSHOT__ {"studyDesign":"Randomized, open-label, 2×2 factorial controlled trial","setting":"Not reported (country and institution type not specified in abstract)","sampleSize":"n=160 adults, allocated equally across four arms (n=40 per group)","population":"Adult patients with confirmed H. pylori infection; specific inclusion/exclusion criteria (e.g., prior eradication attempts, comorbidities, antibiotic resistance testing) not reported in the abstract","intervention":"Arm 1: Clarithromycin-based triple therapy × 14 days; Arm 2: Levofloxacin-based triple therapy × 14 days; Arm 3: Clarithromycin-based triple therapy + lactoferrin × 14 days; Arm 4: Levofloxacin-based triple therapy + lactoferrin × 14 days. Specific drug doses, PPI agent, and lactoferrin dose/formulation not reported in the abstract.","comparator":"Each antibiotic backbone serves as comparator to the other; presence vs. absence of lactoferrin is the factorial comparator","primaryOutcome":"H. pylori eradication assessed by stool antigen testing four weeks after completion of therapy; analyzed by intention-to-treat (ITT) principle","followUp":"Four weeks post-treatment (eradication assessment only; longer-term follow-up not reported)","fundingSource":"Not reported"}
Key findings
In the ITT analysis, eradication rates without lactoferrin were identical in both antibiotic backbone arms: 72.5% for clarithromycin-based and 72.5% for levofloxacin-based triple therapy, indicating no statistically significant difference between the two antibiotics alone (p-value for this specific comparison not reported in the abstract). With lactoferrin supplementation, eradication rates increased to 90.0% in the clarithromycin + lactoferrin arm and 97.5% in the levofloxacin + lactoferrin arm. Pooling across both antibiotic backbones, lactoferrin supplementation improved eradication from 72.5% to 93.8% (p=0.003). The absolute risk difference (ARD) for the lactoferrin effect is 21.3 percentage points (calculated); the number needed to treat (NNT) is approximately 5 (calculated). The overall four-group comparison reached statistical significance (p=0.003). Whether the interaction term between antibiotic backbone and lactoferrin was formally tested is not reported in the abstract. Specific adverse event rates, tolerability data, and safety outcomes are not reported in the provided abstract excerpt.
Practice implications
This trial establishes that adjunctive lactoferrin meaningfully and statistically significantly improved H. pylori eradication rates over 14 days of triple therapy in this population, with a clinically important absolute gain of ~21 percentage points and an NNT of ~5. The finding that levofloxacin + lactoferrin achieved 97.5% eradication is particularly notable against a backdrop of rising clarithromycin resistance, as it approaches the ≥90% threshold recommended by major guidelines (ACG, European Maastricht VI) before a regimen is considered acceptable for empiric use. However, several critical caveats limit immediate practice translation: (1) No antibiotic susceptibility or resistance testing is reported, making it impossible to determine whether eradication differences reflect true pharmacological effects or unmeasured resistance profiles; (2) the population is incompletely characterized — prior treatment history, H. pylori strain type, geographic resistance prevalence, and patient comorbidities are not described; (3) the specific antibiotic doses, PPI used, and lactoferrin formulation and dose are not reported in the abstract, precluding direct protocol replication; (4) the open-label design introduces performance and detection bias; (5) the sample size of 40 per group is small and the trial may be underpowered to detect arm-specific interaction effects; and (6) only abstract data are available for this summary — the full publication may contain additional efficacy, safety, and mechanistic data that materially alter interpretation. Results should be considered hypothesis-generating and context-generating rather than immediately practice-changing, particularly given region-specific variation in fluoroquinolone resistance rates. __LIMITATIONS__ Open-label design with no blinding of participants, clinicians, or outcome assessors — introduces performance and detection bias for both efficacy and tolerability outcomes,Small per-group sample size (n=40 per arm) limits power to detect interaction effects between antibiotic backbone and lactoferrin, and inflates the risk of type I and type II error in subgroup comparisons,Absence of antibiotic susceptibility testing (phenotypic or genotypic) means that the baseline clarithromycin and levofloxacin resistance rates in this cohort are unknown, making it impossible to attribute eradication differences to treatment effects vs. resistance-distribution imbalance,Stool antigen test used at four weeks post-therapy: some guidelines recommend a minimum of four weeks off PPI and antibiotics; the adequacy of the washout period is not described,Population characterization is incomplete: prior H. pylori eradication history, CYP2C19 genotype (affecting PPI metabolism), smoking status, compliance rates, and geographic/institutional setting are not reported,Specific antibiotic doses, PPI agent and dose, lactoferrin dose, formulation, and sourcing (bovine vs. recombinant) are not reported in the abstract, limiting protocol reproducibility,Four-week follow-up assesses only microbiological eradication; clinical outcomes (symptom resolution, ulcer healing, cancer prevention) are not reported,Funding source is not disclosed — potential for sponsorship bias cannot be assessed,No formal interaction test between antibiotic backbone and lactoferrin reported, so whether lactoferrin's benefit is truly consistent across both regimens or driven by one arm cannot be determined,Generalizability is uncertain: regional fluoroquinolone resistance rates vary markedly globally, and levofloxacin-based regimens are not universally appropriate as first-line therapy in high-resistance areas,Summary based on abstract only — full-text data including per-protocol analysis, adverse events, dropout rates, and statistical modeling may alter conclusions __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ Adjunctive lactoferrin supplementation statistically and clinically significantly improved H. pylori eradication rates by approximately 21 percentage points (NNT ~5) across both clarithromycin- and levofloxacin-based 14-day triple therapy in this small open-label RCT (n=160), with levofloxacin + lactoferrin achieving 97.5% ITT eradication. However, the absence of susceptibility testing, incomplete population characterization, open-label design, small per-arm sample size, and abstract-only availability preclude confident practice change at this time. These results are hypothesis-generating and warrant confirmation in a larger, blinded, susceptibility-stratified trial before routine lactoferrin co-prescription can be recommended.